J
José A. López
Researcher at University of Washington
Publications - 252
Citations - 15128
José A. López is an academic researcher from University of Washington. The author has contributed to research in topics: Platelet & Platelet membrane glycoprotein. The author has an hindex of 61, co-authored 245 publications receiving 13678 citations. Previous affiliations of José A. López include University of Washington Medical Center & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Tissue-factor–bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation
TL;DR: A mechanism by which all of the membrane-bound reactions of the coagulation system can be localized to the surface of activated platelets is suggested.
Journal ArticleDOI
In vitro microvessels for the study of angiogenesis and thrombosis.
Ying Zheng,Junmei Chen,Michael Craven,Nakwon Choi,Samuel Totorica,Anthony Diaz-Santana,Pouneh Kermani,Barbara L. Hempstead,Claudia Fischbach-Teschl,José A. López,Abraham D. Stroock +10 more
TL;DR: The lithographic technique used to form endothelialized microfluidic vessels within a native collagen matrix is described and the morphology, mass transfer processes, and long-term stability of the endothelium are characterized.
Journal ArticleDOI
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Kevin A. Hay,Kevin A. Hay,Laila-Aicha Hanafi,Daniel Li,Juliane Gust,W. Conrad Liles,Mark M. Wurfel,José A. López,Junmei Chen,Dominic W. Chung,Susanna Harju-Baker,Sindhu Cherian,Xueyan Chen,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle +18 more
TL;DR: Severe CRS was characterized by hemodynamic instability, capillary leak, and consumptive coagulopathy, and Angiopoietin-2 and von Willebrand factor, which are biomarkers of endothelial activation, were increased during severe CRS and also before lymphodepletion in patients who subsequently developed CRS.
Journal ArticleDOI
Platelet Glycoprotein Ibα Is a Counterreceptor for the Leukocyte Integrin Mac-1 (Cd11b/Cd18)
Daniel I. Simon,Zhiping Chen,Hui Xu,Chester Q. Li,Jing-fei Dong,Larry V. McIntire,Christie M. Ballantyne,Li Zhang,Mark I. Furman,Michael C. Berndt,José A. López +10 more
TL;DR: The platelet counterreceptor is identified as glycoprotein (GP) Ibα, a component of the GP Ib-IX-V complex, the platelet von Willebrand factor (vWf) receptor, which provides a molecular target for disrupting leukocyte–platelet complexes that promote vascular inflammation in thrombosis, atherosclerosis, and angioplasty-related restenosis.
Journal ArticleDOI
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille N. Abboud,Ellin Berman,Adam D. Cohen,Jorge E. Cortes,Daniel J. DeAngelo,Michael W. Deininger,Steven M. Devine,Brian J. Druker,Amir T. Fathi,Elias Jabbour,Madan Jagasia,Hagop M. Kantarjian,Jean Khoury,Pierre Laneuville,Richard A. Larson,Jeffrey H. Lipton,Joseph O. Moore,Tariq I. Mughal,Susan O'Brien,Javier Pinilla-Ibarz,Alfonso Quintás-Cardama,Jerald P. Radich,Vishnu Reddy,Charles A. Schiffer,Neil P. Shah,Paul J. Shami,Richard T. Silver,David S. Snyder,Richard Stone,Moshe Talpaz,Ayalew Tefferi,Richard A. Van Etten,Meir Wetzler,Elisabetta Abruzzese,Jane F. Apperley,Massimo Breccia,Jenny Byrne,Francisco Cervantes,Ekaterina Chelysheva,Richard E. Clark,Hugues de Lavallade,Iryna Dyagil,Carlo Gambacorti-Passerini,John M. Goldman,Ibrahim C. Haznedaroglu,Henrik Hjorth-Hansen,Tessa L. Holyoake,Brian J. P. Huntly,Philipp le Coutre,Elza Lomaia,Francois-Xavier Mahon,David Marin-Costa,Giovanni Martinelli,Jiri Mayer,Dragana Milojkovic,Eduardo Olavarria,Kimmo Porkka,Johan Richter,Philippe Rousselot,Giuseppe Saglio,Güray Saydam,Jesper Stentoft,Anna G. Turkina,Paolo Vigneri,Andrey Zaritskey,Alvaro Aguayo,Manuel Ayala,Israel Bendit,Raquel Bengió,Carlos Best,Eduardo Bullorsky,Eduardo Cervera,Carmino DeSouza,Ernesto Fanilla,David Gómez-Almaguer,Nelson Hamerschlak,José A. López,Alicia Magarinos,Luis Meillon,Jorge Milone,Beatriz Moiraghi,Ricardo Pasquini,Carolina Pavlovsky,Guillermo J. Ruiz-Argüelles,Nelson Spector,Christopher Arthur,Peter Browett,Andrew Grigg,Jianda Hu,Xiao-Jun Huang,Timothy P. Hughes,Qian Jiang,Saengsuree Jootar,Dong-Wook Kim,Hemant Malhotra,Pankaj Malhotra,Itaru Matsumura,Junia V. Melo,Kazunori Ohnishi,Ryuzo Ohno,Tapan Saikia,Anthony P. Schwarer,Naoto Takahashi,Constantine S. Tam,Tetsuzo Tauchi,Kensuke Usuki,Jianxiang Wang,Fawzi Abdel-Rahman,Mahmoud Aljurf,Ali Bazarbachi,Dina Ben Yehuda,Naeem Chaudhri,Muheez A. Durosinmi,Hossam Kamel,Vernon J. Louw,Bassam Francis Matti,Arnon Nagler,Pia Raanani,Ziad Salem +118 more
TL;DR: There is a need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.